Key Highlights

  • ITOC shares trading down 21.41% today to $2.24, a Penny Stock price under $5.
  • The stock sits below its prior 52-week low of $2.33, within a range that reached $18.40.
  • A 16-for-1 share consolidation took effect on October 6, 2026, cutting Class A shares from about 109.4 million to 6.8 million.
  • Nasdaq had set an October 19, 2026 deadline to restore a closing bid price of at least $1.00.
  • Trailing Revenue is about $556,430 against a net loss of roughly $8.9 million, per data providers.

Shares Slide Below the 52-Week Low Weeks After a 16-for-1 Consolidation

iTonic Holdings (NASDAQ:ITOC) shares are trading down 21.41% today at $2.24. No company announcement explaining today's move was identified, so no specific catalyst can be confirmed.

The stock closed at $2.80 on October 23, down 13.31% that day, with a 52-week range of $2.33 to $18.40. Today's price is below that low, extending a decline in which the stock has fallen far from its 52-week high.

Nasdaq Bid Price Deadline Drove the Share Consolidation

Nasdaq granted iTonic a 180-day extension in April 2026 to regain compliance with its $1.00 minimum bid price rule, setting an October 19, 2026 deadline. Shareholders approved the changes at an extraordinary general meeting on September 9.

The 16-for-1 consolidation took effect on October 6 under the unchanged ITOC symbol. Class A shares outstanding fell from about 109,382,000 to roughly 6,836,375, and Class B shares from about 7,668,000 to 479,250. The company also raised authorized Share Capital from $50,000 to $800,000, adding unissued shares without changing the number outstanding.

Par value per share rose from $0.0001 to $0.0016, the CUSIP identifier changed, and fractional entitlements were rounded up to the next whole share. Had the bid price requirement not been met by the deadline, Nasdaq indicated it would issue a delisting notice, which the company could appeal to a hearings panel.

The company stated that it could not assure investors it would regain or maintain compliance. A confirmation of compliance was not found in the sources reviewed.

Brachytherapy Planning Business Operates on Under $600,000 of Annual Revenue

Founded in 1998, iTonic operates through its Beijing-based Subsidiary Beijing Feitian Zhaoye Technology. It develops and sells treatment planning software and devices for brachytherapy, a form of radiation therapy that places radioactive sources inside the body, led by a planning system known as FTTPS.

Revenue was $523,031 in 2025, up 16.7% from $448,196 in 2024. Trailing twelve-month revenue is about $556,430, up 82.3%, according to data providers.

The same data shows a trailing net loss of about $8.92 million, though a separate summary of 2025 reports a loss near $5.10 million, so the two figures may cover different periods. Market Capitalization was about $20.48 million at the October 23 price, based on roughly 7.32 million shares outstanding. At today's price, that share count implies a value near $16.4 million, calculated rather than reported.

Post-Consolidation Trading and Compliance Confirmation Remain the Items to Follow

With no fresh announcement behind today's decline, attention turns to whether iTonic confirms compliance with Nasdaq's bid price rule and how the share price settles after a consolidation that shrank the share count by 94%. Future filings should clarify financing needs, given the net loss, the modest revenue base and the expanded pool of authorized but unissued shares now available to the company.